Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on March 20, 2024
Conference Call Details: |
|
Date: |
Wednesday, March 20, 2024 |
Time: |
8:00 a.m. Eastern time |
Participant Dial-in: |
1-833-953-2434 ( |
Replay Dial-in (Passcode 6766979): (telephonic replay through March 27, 2024) |
1-877-344-7529 ( |
Webcast: (online replay through March 20, 2025) |
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305397352/en/
Jamie Webb
Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737
Source: Harrow, Inc.